Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

NCT04634825 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

62

Enrollment

INDUSTRY

Sponsor class

Stopped Based on internal review of safety data

Conditions

Head and Neck Cancer
Head and Neck Neoplasms
Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Enoblituzumab
BIOLOGICAL: Retifanlimab
BIOLOGICAL: Tebotelimab

Sponsor

MacroGenics